衰弱与心血管代谢性共病的共享发病机制研究进展

doi:10.3969/j.issn.1003-9198.2026.10.012

摘要/Abstract

摘要： 衰弱是一种以多系统功能减退为核心的老年综合征,在人口老龄化加速的背景下,其与心血管代谢性共病在老年人群中的共存现象日益凸显,二者相互促进,加快患者临床结局的恶化。本文旨在系统综述衰弱与心血管代谢性共病之间共享的病理生理网络,深入探讨两者之间相互交织的生物学机制。临床研究显示,慢性炎症是这一网络的核心驱动力,细胞衰老、肠道菌群紊乱、神经内分泌失调、胰岛素抵抗、线粒体功能障碍及肥胖等多种病理机制,通过加重机体的慢性炎症状态,最终共同导致衰弱和多种心血管代谢性疾病的发生。理解这一复杂的机制网络,不仅有助于阐明二者在病因学上的紧密联系,也为临床早期识别、综合干预提供了理论依据。

关键词: 衰弱, 心血管代谢性共病, 心血管代谢性疾病, 慢性炎症, 发病机制

Abstract: Frailty is a geriatric syndrome characterized by multisystem functional decline. Against the backdrop of accelerating population aging, its coexistence with cardiometabolic multimorbidity in the elderly population has become increasingly prominent, with the two conditions reinforcing each other and exacerbating clinical outcomes. This article aims to systematically review the shared pathophysiological network between frailty and cardiometabolic multimorbidity, and to explore the intertwined biological mechanisms underlying their interaction. Clinical studies have identified chronic inflammation as the core driver of this network. Various pathological mechanisms, including cellular senescence, gut microbiota dysbiosis, neuroendocrine dysregulation, insulin resistance, mitochondrial dysfunction, and obesity, ultimately contribute to the development of both frailty and multiple cardiometabolic diseases by exacerbating chronic inflammation. Elucidating this complex mechanistic network not only helps to clarify the close etiological link between the two but also provides a theoretical basis for early clinical identification and comprehensive intervention, thereby improving health management in the elderly population.

Key words: frailty, cardiometabolic multimorbidity, cardiometabolic disease, chronic inflammation, pathogenesis

中图分类号:

R592
R54

严粟, 王泽文, 陈漪澜, 陈蕊, 丁思雨, 汤忠泉, 欧婷. 衰弱与心血管代谢性共病的共享发病机制研究进展[J]. 实用老年医学, 2026, 40(10): 1038-1042.

YAN Su, WANG Zewen, CHEN Yilan, CHEN Rui, DING Siyu, TANG Zhongquan, OU Ting. Research progress on the shared pathogenesis of frailty and cardiometabolic multimorbidity[J]. Practical Geriatrics, 2026, 40(10): 1038-1042.

参考文献

[1] 郭郡郡. 中国城市群人口老龄化的时空演变与影响因素: 基于全国人口普查数据的分析[J]. 云南民族大学学报(哲学社会科学版), 2023, 40(4): 84-94.
[2] 中华医学会老年医学分会. 老年患者衰弱评估与干预中国专家共识[J]. 中华老年医学杂志, 2017, 36(3): 251-256.
[3] VERONESE N, CUSTODERO C, CELLA A, et al. Prevalence of multidimensional frailty and pre-frailty in older people in different settings: a systematic review and meta-analysis[J]. Ageing Res Rev, 2021, 72: 101498.
[4] 苏恩慧, 王永恒, 徐苒钧, 等. 心血管代谢性疾病病人营养不良风险预测模型的范围综述[J]. 循证护理, 2025, 11(18): 3745-3753.
[5] HAN Y, HU Y, YU C, et al. Lifestyle, cardiometabolic disease, and multimorbidity in a prospective Chinese study[J]. Eur Heart J, 2021, 42(34): 3374-3384.
[6] 杨小芹, 金秀华, 郭思佳, 等. 全科门诊慢性病老年患者衰弱与共病现状及其影响因素调查[J]. 海南医学, 2025, 36(7): 1032-1037.
[7] MITNITSKI A B, MOGILNER A J, ROCKWOOD K. Accumulation of deficits as a proxy measure of aging[J].Sci World J, 2001, 1: 323-336.
[8] FAN J, YU C, GUO Y, et al. Frailty index and all-cause and cause-specific mortality in Chinese adults: a prospective cohort study[J].Lancet Public Health, 2020, 5(12): e650-e660.
[9] KOJIMA G, ILIFFE S, WALTERS K. Frailty index as a predictor of mortality: a systematic review and meta-analysis[J]. Age Ageing, 2018, 47(2): 193-200.
[10] 朱俊, 郑谌. 不同Fried衰弱分级对老年共病患者及代谢综合征的影响[J]. 中国老年学杂志, 2021, 41(21): 4626-4628.
[11] ROCKWOOD K, SONG X, MACKNIGHT C, et al. A global clinical measure of fitness and frailty in elderly people[J]. CMAJ, 2005, 173(5): 489-495.
[12] CHURCH S, ROGERS E, ROCKWOOD K, et al. A scoping review of the clinical frailty scale[J]. BMC Geriatr, 2020, 20(1): 393.
[13] 邓瑞冰, 王晓明, 张伟, 等. 慢性炎症与衰弱的研究进展[J]. 国际老年医学杂志, 2025, 46(5): 513-517.
[14] NISHIKAWA H, ASAI A, FUKUNISHI S, et al. Metabolic syndrome and sarcopenia[J]. Nutrients, 2021, 13(10): 3519.
[15] KAWASAKI N, ASADA R, SAITO A, KANEMOTO S, et al. Obesity-induced endoplasmic reticulum stress causes chronic inflammation in adipose tissue[J]. Sci Rep, 2012, 2: 799.
[16] BAECHLE J J, CHEN N, MAKHIJANI P, et al. Chronic inflammation and the hallmarks of aging[J]. Mol Metab, 2023, 74: 101755.
[17] CHAIT A, DEN HARTIGH L J. Adipose tissue distribution, inflammation and its metabolic consequences, including diabetes and cardiovascular disease[J]. Front Cardiovasc Med, 2020, 7: 22.
[18] FERRUCCI L, FABBRI E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty[J]. Nat Rev Cardiol, 2018, 15(9): 505-522.
[19] ASHRAF J V, AL HAJ ZEN A. Role of vascular smooth muscle cell phenotype switching in arteriogenesis[J]. Int J Mol Sci, 2021, 22(19): 10585.
[20] 王一斐, 张萍. 心房颤动与炎症反应之交互关系[J]. 中国心血管杂志, 2023, 28(1): 62-66.
[21] MARTINI H, PASSOS J F. Cellular senescence: all roads lead to mitochondria[J]. FEBS J, 2023, 290(5): 1186-1202.
[22] CHAIB S, TCHKONIA T, KIRKLAND J L. Cellular senescence and senolytics: the path to the clinic[J]. Nat Med, 2022, 28(8): 1556-1568.
[23] 王学, 任丽君, 张英为, 等. 细胞衰老分子机制的研究进展[J]. 中国老年学杂志, 2023, 43(1): 250-253.
[24] DINAKIS E, NAKAI M, GILL P, et al. Association between the gut microbiome and their metabolites with human blood pressure variability[J]. Hypertension, 2022, 79(8): 1690-1701.
[25] 韦宜汝, 兰映吉, 黄颉刚. 基于两样本孟德尔随机化分析的肠道菌群与衰弱的关联性研究[J]. 广西医学, 2023, 45(23): 2880-2885.
[26] ZHANG Y, ZHANG S, LI B, et al. Gut microbiota dysbiosis promotes age-related atrial fibrillation by lipopolysaccharide and glucose-induced activation of NLRP3-inflammasome[J]. Cardiovasc Res, 2022, 118(3): 785-797.
[27] 李永浩, 陈丽如, 奚恒, 等. 肠道菌群失调在老年衰弱发生发展中的作用及机制[J]. 中华临床营养杂志, 2025, 33(5): 340-346.
[28] SHEN X, LI L, SUN Z, et al. Gut microbiota and atherosclerosis-focusing on the plaque stability[J]. Front Cardiovasc Med, 2021, 8: 668532.
[29] 路怀志, 池尧, 赵辉, 等. 肠道菌群代谢物TMAO对兔动脉粥样硬化斑块形成及狭窄程度的影响[J]. 中国实验诊断学, 2024, 28(4): 478-482.
[30] 任卓, 姚晓东. 内分泌激素与老年衰弱相关性的研究进展[J]. 国际老年医学杂志, 2023, 44(6): 743-746.
[31] PERAZZA L R, BROWN-BORG H M, THOMPSON L V. Physiological systems in promoting frailty[J]. Compr Physiol, 2022, 12(3): 3575-3620.
[32] 张爽, 杨孟丽, 叶松岩, 等. 不同性别老年糖尿病患者衰弱现状及影响因素分析[J]. 护理实践与研究, 2022, 19(16): 2390-2396.
[33] 刘雅萌, 阳晓丽, 张彩虹. 老年高血压相关性衰弱的发病机制及运动干预机制的研究进展[J]. 中国全科医学, 2023, 26(5): 635-640.
[34] 王亚楠, 米叶赛·艾尼瓦尔, 郑淑娟, 等. 阻断肾素血管紧张醛固酮系统类药物干预衰弱的研究进展[J]. 中国老年学杂志, 2025, 45(12): 3060-3064.
[35] KE Z, WEN H, HUANG R, et al. Long-term insulin resistance is associated with frailty, frailty progression, and cardiovascular disease[J]. J Cachexia Sarcopenia Muscle, 2024, 15(4): 1578-1586.
[36] ZHAO Y C, WU S Q, LI J K, et al. Predictive value of the combined triglyceride-glucose and frailty index for cardiovascular disease and stroke in two prospective cohorts[J]. Cardiovasc Diabetol, 2025, 24(1): 318.
[37] SANZ-CÁNOVAS J, LÓPEZ-SAMPALO A, COBOS-PALACIOS L, et al. Management of type 2 diabetes mellitus in elderly patients with frailty and/or sarcopenia[J]. Int J Environ Res Public Health, 2022, 19(14): 8677.
[38] 欧阳文慧, 欧阳晓俊. 肌少症与血管内皮功能障碍关系的研究进展[J]. 中华老年心脑血管病杂志, 2026, 28(2): 268-270.
[39] 徐率轩, HUANG Wei, 孔二艳, 等. 氧化应激在衰弱发病机制中的作用[J]. 中华老年多器官疾病杂志, 2022, 21(11): 858-862.
[40] JIA G, BAI H, MATHER B, et al. Diabetic vasculopathy: molecular mechanisms and clinical insights[J]. Int J Mol Sci, 2024, 25(2): 804.
[41] 曹龙钰, 邵秀芬, 孙文霞. 老年肌少性肥胖与心血管疾病相关性的研究进展[J]. 慢性病学杂志, 2025, 26(11): 1633-1636, 1640.
[42] HE L, ZHANG L, FU S, et al. Association between different inflammatory markers and generalized abdominal obesity: a cross-sectional study[J]. Obes Surg, 2024, 34(9): 3372-3381.